MEETING PROGRAM

PRESENTED BY
Adam Bass, MD & TargetCancer Foundation
Thank you for joining us virtually for the 2021 Think Tank on Advancing Gastroesophageal Cancer Research. We are sorry that we cannot meet in person again this year, but we are excited for the broader international reach that our virtual format allows. While we cannot replicate the conversations and networking that make the Think Tank so valuable, we hope that the presentations over these two days will still lead to new ideas and collaborative opportunities.

We are grateful to all of our speakers for sharing their expertise over the next two days. Thank you also to the members of our Planning Committee who worked with us to facilitate this meeting: Drs. Julian Abrams, Daniel Catenacci, Jim Goldenring, Sam Klempner, Gary Falk, Monika Laszkowska, and Matthew Stachler.

Finally, we would like to express our sincere thanks to our sponsor Taiho Oncology for their generous support of this meeting.

We look forward to gathering again in person in 2022.

Jim Palma
TargetCancer Foundation

Adam Bass, MD
Columbia University Irving Medical Center
### AGENDA

**THURSDAY, NOVEMBER 18, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:50-8:58a</td>
<td>WELCOME &amp; INTRODUCTIONS</td>
<td></td>
</tr>
<tr>
<td>9:00-10:25a</td>
<td>MAIN SESSION</td>
<td><strong>Epidemiology of Gastric Cancer: With a Focus on Diffuse-Type Tumors</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Constanza Camargo, PhD, <em>National Cancer Institute</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Unique Behavior of Early Stage Gastric Cancers Due to CDH1</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeremy L. Davis, MD, <em>National Cancer Institute</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Biomarkers for Early Detection of Diffuse Gastric Cancer Model</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sandra Ryeom, PhD, <em>Columbia University Irving Medical Center</em></td>
</tr>
<tr>
<td>10:25-10:35a</td>
<td>STRETCH &amp; BYO COFFEE</td>
<td></td>
</tr>
<tr>
<td>10:35-11:00a</td>
<td>RAPID-FIRE ABSTRACT PRESENTATIONS</td>
<td><strong>Prognostic and Predictive Gene Signature of 5FU/platinum and anti-PD1 inhibitors for Gastric Cancer</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tae Hyun Hwang, PhD, <em>Mayo Clinic</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Trop2+CD133+CD166+ Dysplastic Cells Are De Novo Stem Cells Driving Carcinogenic Transition of Dysplasia to Gastric Adenocarcinoma</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eunyoung Choi, PhD, <em>Vanderbilt University Medical Center</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Study in the Department of Defense Serum Repository</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Omonefe Omofuma, PhD, MS, <em>National Cancer Institute</em></td>
</tr>
<tr>
<td>11:25-12:15p</td>
<td>MAIN SESSION CONTINUED</td>
<td><strong>Understanding Gastric Cancer Ecosystems by Single-Cell Sequencing</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Linghua Wang, MD, PhD, <em>MD Anderson Cancer Center</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>The Role of SOX9 in Gastroesophageal Cancers</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jaffer Ajani, PhD, <em>MD Anderson Cancer Center</em></td>
</tr>
<tr>
<td>12:20-12:30p</td>
<td>CLOSING REMARKS</td>
<td></td>
</tr>
</tbody>
</table>
AGENDA
FRIDAY, NOVEMBER 19, 2021

8:50-8:58a  WELCOME & INTRODUCTIONS

9:00-10:25a  MAIN SESSION

- Current Landscape and Future Perspective of Immunotherapy for GE Cancer
  Kohei Shitara, MD, National Cancer Center Hospital East

- Immunotherapy in GC: What is Next?
  Jeeyun Lee, MD, Samsung Medical Center

- Evaluating Gastroesophageal Cancer Dependencies by Rapid Image-Based Ex Vivo Biosensors
  Mushriq Al-Jazrawe, PhD, Broad Institute of MIT and Harvard

10:25-10:35a  STRETCH & BYO COFFEE

10:35-10:50a  TCF-001 TRACK INTRODUCTION
  Jim Palma, Executive Director, TargetCancer Foundation

10:55-12:20p  MAIN SESSION CONTINUED

- Machine Learning in Barrett’s Endoscopy
  Jacques Bergman, MD, PhD, Amsterdam University Medical Centre

- Towards Earlier Diagnosis of Barrett’s Neoplasia
  Rebecca Fitzgerald, MD, University of Cambridge

- Tracking the Origin and Developmental Trajectory of Barrett’s Esophagus Using Single Cell RNA Sequencing
  Karol Nowicki-Osuch, PhD, Irving Institute for Cancer Dynamics, Columbia University

12:20-12:30p  CLOSING REMARKS
SPEAKERS
Day 1

JAFFER AJANI, PHD
MD Anderson Cancer Center

Click to learn more

CONSTANZA CAMARGO, PHD
National Cancer Institute

Click to learn more

JEREMY L. DAVIS, MD
National Cancer Institute

Click to learn more
Twitter: @JeremyLDavisMD

SANDRA RYEOM, PHD
Columbia University Irving Medical Center

Click to learn more

LINGHUA WANG, MD, PHD
MD Anderson Cancer Center

Click to learn more
Twitter: @IamLinghua
SPEAKERS
Day 2

JACQUES BERGMAN, MD, PHD
Amsterdam University Medical Centre

Click to learn more

REBECCA FITZGERALD
University of Cambridge

Click to learn more
Twitter: @RFitzgerald_lab

JEYUN LEE, MD
Samsung Medical Center

Click to learn more
Twitter: @JeeyunM

KAROL NOWICKI-OSUCH, PHD
Irving Institute for Cancer Dynamics, Columbia University

Click to learn more
Twitter: @doctor_kno

KOHEI SHITARA, MD
National Cancer Center Hospital East

Click to learn more
Twitter: @koheishitara
TOP-TIER ABSTRACT

*Mushriq Al-Jazrawe, PhD,* Broad Institute of MIT and Harvard
Evaluating Gastroesophageal Cancer Dependencies by Rapid Image-Based Ex Vivo Biosensors

RAPID-FIRE ABSTRACTS

*Tae Hyun Hwang, PhD,* Mayo Clinic
Prognostic and Predictive Gene Signature of 5FU/platinum and Anti-PD1 Inhibitors for Gastric Cancer

*Eunyoung Choi, PhD,* Vanderbilt University Medical Center
Trop2+CD133+CD166+ Dysplastic Cells Are De Novo Stem Cells Driving Carcinogenic Transition of Dysplasia to Gastric Adenocarcinoma

*Omonofe Omofuma, PhD, MS,* National Cancer Institute
Circulating Inflammation Biomarkers and the Risk of Esophageal Adenocarcinoma: A Study in the Department of Defense Serum Repository
At Taiho Oncology, our mission is to improve the lives of cancer patients, their families, and their caregivers. Taiho continues to deliver innovative products to the U.S. and global marketplace. The oncology patient, and their support systems, are at the center of our every activity.

© TAIHO ONCOLOGY, INC. 2/2020 All rights reserved. T01-PM-US-0160 V2
TCF-001 TRACK is a rare cancer precision medicine clinical trial, NCT04504604.

TRACK provides participating rare cancer patients and their physicians with personalized, actionable information to potentially inform treatment, as well as recommendations for on-label, off-label, or clinical trial treatments from an expert panel of rare cancer clinicians and scientists. Simultaneously, TRACK generates critical genomic data to drive a better understanding of often overlooked rare cancers.

**TRACK is currently open to enrollment for:**

- Patients with any rare cancer (defined as a solid tumor or lymphoma occurring in less than 6 per 100,000 people per year in the US). TRACK will specifically enroll 100 patients with cholangiocarcinoma.
- Patients with cancer of unknown primary.

**How TRACK Works:**

- Qualifying patients can enroll in TRACK from their home using a remote consenting system, allowing full participation with no requirement to travel or change their treating physician.
- Patients enrolled in TRACK receive comprehensive genomic profiling (FoundationOne CDx and FoundationOne Liquid CDx) at no cost.
- The TRACK Virtual Molecular Tumor Board, composed of field-leading rare cancer experts, convenes to review the resulting reports and other data, and provides treatment recommendations to the patient and their treating physician.
- Over the year that follows, the TCF study team collects updated study-related medical information from each patient. In addition, comprehensive genomic profiling of blood is repeated multiple times to identify new alterations which could potentially drive additional treatment recommendations.

To learn more about TRACK and how to enroll, visit www.targetcancerfoundation.org/track, or call 617-299-0389.
TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.